As I have written about previously, the IP and competitive landscape for mRNA and lipid nanoparticles is complex. Pioneers, mid-stage, and new market entrants must take careful consideration of this landscape and develop a...more
Several patent litigations have been filed involving mRNA pioneers such as Moderna, Inc. and BioNTech, Inc. (with Pfizer) over the past year relating to sales of the Moderna and BioNTech/Pfizer COVID-19 vaccine products...more
On January 4, 2022, Judge Andrews from the United States District Court for the District of Delaware denied Sarepta Therapeutics, Inc.’s (“Sarepta”) Rule 12(b)(6) motion to dismiss a complaint for infringement of U.S. Patent...more
In April of 2021, we provided a three-part series relating to the IP and Competitive Landscape for the mRNA market. In this post we provide a 2021 year in review update on mRNA pioneers and key players and offer additional...more
Universities and certain colleges in the United States (US) spend billions of dollars on research and development (R&D) each year to advance knowledge across the gamut of Arts, Humanities, and Science, Technology,...more
In Part I of this series providing a summary of the mRNA IP and competitive landscape through one year of the COVID-19 pandemic, we focused on market players BioNTech, Moderna and CureVac; in Part II, we discussed Translate...more
Founders of an emerging company must decide early on in its growth cycle whether to require employees to assign their inventions (including rights to patent and patent applications –collectively “patent rights”) to the...more
3/29/2021
/ Artificial Intelligence ,
Assignments ,
Confidential Information ,
Fiduciary Duty ,
Intellectual Property Protection ,
Inventors ,
Joint Inventors ,
Patent Applications ,
Patents ,
Trade Secrets ,
USPTO
Moderna, one of the global leaders in developing a safe and effective vaccine to combat COVID-19, appears poised to get through clinical trials with a vaccine that is based on mRNA technology. As was recently announced,...more
11/16/2020
/ Coronavirus/COVID-19 ,
Final Written Decisions ,
Inter Partes Review (IPR) Proceeding ,
Life Sciences ,
Moderna Inc. ,
Patent Trial and Appeal Board ,
Patents ,
Pharmaceutical Patents ,
Popular ,
USPTO ,
Vaccinations
Last month, Moderna Therapeutics, one of the global leaders in the race to produce a COVID-19 vaccine, made the following statement regarding enforcement of its patents:
We feel a special obligation under the current...more
11/10/2020
/ Bayh-Dole Act ,
Biotechnology ,
Coronavirus/COVID-19 ,
Department of Defense (DOD) ,
European Commission ,
Inter Partes Review (IPR) Proceeding ,
Life Sciences ,
Moderna Inc. ,
Patent Invalidity ,
Patent Ownership ,
Patents ,
Pharmaceutical Patents ,
Popular ,
Research and Development ,
USPTO ,
Vaccinations